The organisation loses the contractual and procedural guardrails HIPAA expects before disclosure. That creates exposure around permitted use, required safeguards, and breach response, and it can force the covered entity into remediation or termination decisions after a violation is discovered. In practice, the risk is both regulatory and operational because the partner is handling sensitive patient information without clear rules.
What breaks when PHI is shared before the agreement exists
Without a HIPAA compliant agreement, the disclosure is no longer anchored to the partner’s documented obligations for permitted use, safeguarding, reporting, and return or destruction of data. That shifts the event from a controlled business arrangement into an exposure that may need rapid legal, privacy, and security review, because the covered entity cannot rely on the partner to meet the expected handling standard.
For covered entities, the practical problem is not just that an agreement is missing at the moment of transfer. It is that the organisation has weakened the control boundary around PHI and may now have to assess whether the partner’s access should be suspended, narrowed, or re-papered before further exchange continues.
That is why identity and access governance matters here even though the core issue is contractual. Once PHI leaves the covered entity, the organisation needs clear rules for who can receive it, under what purpose, and with what safeguards. The absence of those rules makes it harder to prove that the disclosure was appropriately controlled, especially if the partner is operating as a downstream custodian of sensitive data. Identity Security Regulatory Map
Why the missing agreement changes the compliance and operating posture
A HIPAA compliant agreement is not just paperwork. It is the mechanism that defines permitted processing, minimum safeguards, incident notification expectations, and the conditions under which the relationship can continue. When that mechanism is absent, the covered entity may still have a disclosure pathway, but it lacks the formal guardrails that regulators and auditors expect to see around PHI sharing. Ultimate Guide to NHIs, regulatory and audit perspectives
Operationally, that usually means the organisation must treat the event as a control failure, not a routine vendor exchange. The next steps often include scoping what was shared, whether the partner already received other PHI, whether the recipient can lawfully retain it, and whether any further transfer, backup, or analytics use has already occurred.
That same control gap can also complicate breach analysis. If PHI was disclosed outside the expected contractual framework, the entity may have less confidence that the partner will preserve confidentiality, restrict reuse, or provide timely notification if something goes wrong. In practice, the missing agreement can force the organisation to rebuild assurance after the fact rather than relying on preventive governance. HHS guidance on business associates
What remediation usually looks like after discovery
Once the issue is found, the response is usually a combination of containment, legal review, and documentation. The covered entity has to decide whether the partner can keep PHI access temporarily, whether sharing should stop until the agreement is executed, and whether any prior disclosures need to be revisited for breach or compliance handling.
The strongest response is usually to align the relationship to the actual data flow, not just the contract template. That means confirming the partner’s role, limiting PHI to the minimum required purpose, and making sure the agreement covers the real services being performed rather than a generic vendor label. If the partner is handling PHI in ways that exceed the intended relationship, remediation should focus on narrowing that scope before resuming normal operations.
In mature programmes, this kind of issue also triggers records cleanup. The organisation should be able to show when the gap was discovered, which systems or workflows were affected, what data categories were involved, and what compensating controls were applied while the agreement was brought into place. CDC HIPAA overview
Risk and Threat Considerations
The main risk is uncontrolled handling of PHI by a partner that has not been formally bound to the expected safeguards and limits. That creates exposure to overuse, delayed notification, and broader downstream disclosure if the partner’s processes are weak or if the relationship later ends badly.
Failure mechanism: The covered entity transfers PHI before the partner’s permitted uses, safeguards, reporting duties, and return or destruction obligations are contractually established, so the organisation loses enforceable control over how the data is handled.
Impact: The result can be regulatory exposure, uncertain breach response, forced suspension of sharing, and costly remediation if the disclosure is later judged noncompliant or if the partner mishandles the information.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 provides the primary governance reference for this topic.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | AC-20 — Use of External Systems | Controls PHI sharing to outside parties through approved external use conditions. |
| SA-9 — External System Services | Addresses governance of third-party services that process or host sensitive data. | |
| AU-6 — Audit Record Review, Analysis, and Reporting | Supports review and investigation of unauthorized or improperly governed PHI disclosures. | |
| Recommendation — Restrict PHI exchange to approved external system use and document the conditions before disclosure. Define security and privacy requirements for external services before sending PHI to them. Review disclosure evidence and investigate PHI transfers that occurred without an approved agreement. | ||
Practitioner Guidance
What to prioritise: Confirm whether PHI has already been sent, whether the receiving party is performing a business associate function, and whether any further disclosure should pause until the agreement is executed. If the answer to either scope question is unclear, treat it as a governance problem before it becomes an incident-management problem.
What to verify: The agreement should match the actual service, the actual data types, and the actual operating model. A common mistake is signing a generic template after the fact and assuming it cures an overbroad disclosure path that still exists in practice.
Practitioner takeaway: The key judgment is whether the organisation can still bound, evidence, and defend the partner’s use of PHI, if it cannot, the relationship needs immediate containment and re-authorisation, not just a paper fix.
Related resources from NHI Mgmt Group
- What happens when a HIPAA-covered organisation discloses PHI without authorization?
- How should organisations protect e-PHI if they are not a HIPAA covered entity?
- Who is accountable for HIPAA compliance when third parties handle PHI on behalf of a covered entity?
- What happens when a HIPAA-covered organisation processes California resident data without CPRA-specific controls?
